All In Biotech

Drug Trial Radar · NCT04123444

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/Kilo(kg)/Minute(Min)) in Patients With Septic Shock Induced Endotheliopathy - a Multicentre Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial"

Last checked: Nov 20, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

Oct 30, 2019

Primary completion

Jun 28, 2022

Study completion Jun 28, 2022

Sponsor

Lead sponsor
Jakob Stensballe, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Innovation Fund Denmark; Independent Research Fund Denmark
First posted
Oct 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in up to a total of 380 patients with septic shock suffering from organ failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in septic shock patients suffering from organ failure caused by endothelial breakdown, ultimately improving survival.

Conditions

  • Septic Shock

Interventions

  • IloprostDrug

    Continuously infusion for 72 hours. treatment dose 1 ng/kg/min

  • Isotonic salineDrug

    Continuously infusion for 72 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Sequential Organ Failure Assessment (SOFA)Time frame: Up to 90 days after randomization

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital

    Copenhagen, Denmark

  • Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet

    Copenhagen, Denmark

  • Dept. of Intensive Care, Copenhagen University Hospital Herlev

    Herlev, Denmark

  • Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital

    Hillerød, Denmark

  • Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital

    Hvidovre, Denmark

  • Region Sealand University Hospital

    Køge, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.